CDKN1B and acute lymphoblastic leukemia: Next, we investigated the effects of SKP2 pharmacological blockade on human T-ALL cells by using the small molecule SKP2 inhibitor, C1, developed for its ability to block protein–protein interaction between SKP2 and p27Kip1 [17].